Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Global Payments Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Global Payments Inc trades at $80.89 (market cap $21.67B). The key difference: Global Payments Inc is far larger — about 7.6× Dyne Therapeutics Inc. Common Stock's market cap, and Global Payments Inc pays a 1.22% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Global Payments Inc for 50 Days on average.
| DYN | GPN | |
|---|---|---|
Market Cap | $2.86B | $21.67B |
Volume | 3,341,579 | 1,851,678 |
Sector | Health | Financials |
52-Week High | $26.78 | $94.83 |
52-Week Low | $14.60 | $62.47 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.18B | $39.81B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Global Payments (GPN) trades at $80.89, down 1.43% on the day, with a neutral technical outlook despite recent earnings beats. The company shows strong revenue growth momentum with Q2 2026 EPS of $3.46 beating estimates, while maintaining a P/E of 38.81 and P/B below 1.0. Recent developments include the Genius platform rollout and Worldpay integration driving business expansion.
The stock offers 27% upside to the $102.75 consensus price target with strong analyst support (59% buy ratings), though negative net income margin and rising debt-to-asset ratio to 41.57% present execution risks. Key catalysts include continued Genius adoption while competition and cost pressures remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
